Latest News

Chip stocks are still hot, but one ETF stands out as the better choice given current conditions.

This massive tech company has seen its share price rise more than 12-fold in the past decade.

Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.

The off-price leader continues to deliver strong results, but with a mature U.S. store base, a premium valuation puts pressure on management to find new sources of growth.

Compare portfolio strategies and sector exposures as two leading consumer staples ETFs take different paths to long-term returns.

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

Portfolio breadth, liquidity, and yield set these two sector giants apart.

These well-established companies are on track to deliver more growth.

Compare portfolio makeup, sector weightings, and fund structure to see how these two popular ETFs stack up for long-term investors.

Residential Properties are one of the most important segments of the real estate industry. They represent homes and living spaces designed for individuals

Rocket Lab and Leidos are better-priced space stocks than SpaceX.

The rapid expansion of blockchain technology has created a new generation of decentralized ecosystems where communities play a major role in determining th

Polymarket creator Shayne Coplan advised aspiring entrepreneurs to abandon backup plans and throw themselves into their venture with full energy and passion.

It's not common, but if it applies to you, you'll definitely want to know in advance.

Shares of this global avocado and mango supplier attracted a notable insider buy following a year of declining stock performance.

Ketalar is a medication that physician use as an anaesthetic to induce loss of consciousness. Nether the Controlled Substance Act, wellness experts see Ket

MP Materials already has a mining operation up and running, and it appears to be a sustainable business.

This energy giant is still firing on all cylinders.

The server maker's margins are recovering, and orders are stacking up. But a heavier balance sheet and an open investigation still cloud the picture.

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.

Many investors feared AI could eventually disrupt S&P Global's business model. But the opposite may happen instead.

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

The gift bow was still on the hood. For a lot of parents, that’s the dream ending. Years of school pickups, packed lunches, college planning and financial sacrifices finally lead to one unforgettable graduation

The crypto market moves fast. I checked the receipts from two years ago to see what's changed.

These are the bases you need to cover before that last paycheck arrives.